Abeona Therapeutics Inc. (NASDAQ:ABEO) shares traded up 4.1% during mid-day trading on Tuesday . The company traded as high as $2.56 and last traded at $2.51, with a volume of 137,567 shares trading hands. The stock had previously closed at $2.41.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Wednesday, April 27th. FBR & Co restated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Sunday, May 22nd. Maxim Group restated a “buy” rating and set a $6.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, May 17th. Finally, Rodman & Renshaw restated a “buy” rating and set a $17.00 price objective on shares of Abeona Therapeutics in a report on Wednesday, May 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Abeona Therapeutics has an average rating of “Buy” and a consensus price target of $11.20.

The firm’s market cap is $80.35 million. The firm has a 50-day moving average of $2.70 and a 200-day moving average of $2.67.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.04. Analysts forecast that Abeona Therapeutics Inc. will post ($0.59) EPS for the current year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC boosted its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent SEC filing.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.